



What is claimed is:

1. A compound represented by the formulae



$R_1$  is chosen from  $C_{1-4}$ alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, H,  $OR_9$ ,  $N_3$ ,  $NR_9R_{9a}$ ,  $CO_2R_9$ ,  $SR_9$ , with the exception wherein  $R_1$  is OH,

$R_2$  is selected from the group of H, halogen,  $N_3$ ,  $(CH_2)_mR_5$ ,

$R_3$  and  $R_{3a}$  are individually chosen from the group consisting of H, OH, halogen, CN,  $NO_2$ ,  $N_3$ ,  $SR_9$ ,  $SO_2R_9$ ,  $(CH_2)_mR_5$ ,


$R_4$  and  $R_{4a}$  are selected from the group of H, OH, Halogen, CN,  $NO_2$ ,  $N_3$ ,  $SR_9$ ,  $SO_2R_9$ ,  $(CH_2)_mR_5$ ,

X is selected from the group of H, OH, CN,  $NO_2$ ,  $N_3$ , halogen,

both X and  $(CH_2)_mR_5$  together can be  $=O$ ,  $=N-OH$ ,

$R_5$  and  $R_{5a}$  are selected from the group of H,  $OR_9$ ,  $NR_9R_{9a}$ ,  $C(O)NR_9R_{9a}$ ,  $R_9$ ,  $R_6$ ,  $OR_6$ ,  $CO_2R_9$ ,  $C(O)R_9$ ,

R<sub>6</sub> is chosen from:



R<sub>7</sub> is selected from the group consisting of H, F, SR<sub>8</sub>, OR<sub>8</sub>,

R<sub>8</sub> is chosen from the group of H, alkyl, alkenyl, alkynyl, aryl, and hydroxyprotecting group,

R<sub>9</sub> and R<sub>9a</sub> are independently selected from the group of H, alkyl, alkenyl, alkynyl, and aryl,

Y is chosen from CH<sub>2</sub>, CF<sub>2</sub>, CHF, and O,

Z is chosen from O, S,

B is selected from the group of purine, pyrimidine and heterocycle,

m is 0, 1, 2, 3, or 4,

and pharmaceutically acceptable salts thereof and prodrugs thereof.

2. A pharmaceutical composition containing at least one compound according to claim 1.
3. A method for inhibiting RNA polymerase in a patient by administering to the patient at least one compound according to claim 1 in an amount sufficient to inhibit viral RNA polymerase.
4. The method according to claim 3 wherein said RNA polymerase is selected from the group consisting of HCV, small pox, Ebola virus, and West Nile virus.

5. A method of treating a patient suffering from RNA viral infection by administering to the patient an effective amount of at least one compound according to claim 1.

6. The method according to claim 5 wherein the RNA viral infection is selected from the group consisting of HCV, HBV and Rhino viral infection.